Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Tremlett

Showing results (1-10 of 255) with videos related to

Pageof 26
Sort By:
Nature Reviews. Neurology|September 17, 2025
The multiple sclerosis prodrome: insights into how and when disease startsHelen Tremlett
Neurology|November 8, 2017
Author response: Evaluating the safety of β-interferons in MS: A series of nested case-control studiesHelen Tremlett
Neurology|June 27, 2002
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosisHelen Tremlett
Lancet (London, England)|May 9, 2006
What went wrong in the natalizumab trials Comment?Helen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2025
High-risk populations should be screened for MS: YesHelen Tremlett
Neurology|January 12, 2005
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effectsHelen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2011
Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions--noHelen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 9, 2018
Gut microbiome and pediatric multiple sclerosisHelen Tremlett, Emmanuelle Waubant
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 31, 2017
Primary and secondary progressive MS have a similar age at onset of progression - NOHelen Tremlett, Yinshan Zhao
Journal of Neurology|December 14, 2004
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosisHelen Tremlett, Joel Oger
Pageof 26

Showing results (1-10 of 255) with videos related to

Sort By:
Pageof 26
Nature Reviews. Neurology|September 17, 2025
The multiple sclerosis prodrome: insights into how and when disease startsHelen Tremlett
Neurology|November 8, 2017
Author response: Evaluating the safety of β-interferons in MS: A series of nested case-control studiesHelen Tremlett
Neurology|June 27, 2002
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosisHelen Tremlett
Lancet (London, England)|May 9, 2006
What went wrong in the natalizumab trials Comment?Helen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2025
High-risk populations should be screened for MS: YesHelen Tremlett
Neurology|January 12, 2005
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effectsHelen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2011
Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions--noHelen Tremlett
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 9, 2018
Gut microbiome and pediatric multiple sclerosisHelen Tremlett, Emmanuelle Waubant
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 31, 2017
Primary and secondary progressive MS have a similar age at onset of progression - NOHelen Tremlett, Yinshan Zhao
Journal of Neurology|December 14, 2004
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosisHelen Tremlett, Joel Oger
Pageof 26